219550-95-5Relevant articles and documents
Hederagenin as a triterpene template for the development of new antitumor compounds
Rodríguez-Hernández, Diego,Demuner, Antonio J.,Barbosa, Luiz C.A.,Csuk, René,Heller, Lucie
, p. 57 - 62 (2015)
In this study, a series of novel C-28 esters and amides derivatives of hederagenin (He) were designed and synthesized in attempt to develop potent antitumor agents. Their structures were confirmed by MS, IR, 1H NMR and 13C NMR spectroscopic analyses and their cytotoxic activities were screened in SRB assays using a panel of six human cancer cell lines. Although most of the compounds displayed moderate to high levels of cytotoxic activity they were all more potent than the natural product He. The most active compounds had either an ethylpyrimidinyl (27) or an ethylpyrrolidinyl (28) substituent, with EC50 in the range of 1.1-6.5 μM for six human cancer cell lines. Notably, this corresponds to an approximately 30-fold times greater potency than He.
Highly potent anti-leishmanial derivatives of hederagenin, a triperpenoid from Sapindus saponaria L.
Rodríguez-Hernández, Diego,Barbosa, Luiz C.A.,Demuner, Antonio J.,de Almeida, Raquel M.,Fujiwara, Ricardo T.,Ferreira, Sebasti?o R.
, p. 153 - 159 (2016)
Leishmaniasis is a neglected tropical disease (NTDs), endemic in 88 countries that affect more than 12 million people. Current drugs are limited due to their toxicity, development of biological resistance, length of treatment and high cost. Thus, the search for new effective and less toxic treatments is an urgent need. In this study, we report the synthesis of 3 new amide derivatives of hederagenin (22–24) with yields between 70% and 90%, along with 57 other derivatives of hederagenin (1–21, 25–60) carrying different groups at C-28 previously reported by our group, and the results of their in?vitro ability to inhibit the growth of Leishmania infantum. Some derivatives (3, 4, 44, 49 and 52), showed activity at micromolar level and low toxicity against BGM and HepG2 cells. Moreover, the ability of hederagenin derivatives 3 (IC50?=?9.7?μM), 4 (12?μM), 44 (11?μM) and 49 (2?μM), to prevent proliferation of intracellular amastigote forms of L.?infantum and their higher selectivity index and low toxicity compared to commercial positive drug control of choice (potassium antimonyl tartrate trihydrate) (IC50?=?80?μM, SI?=?0.1), make these compounds promising candidates for the treatment of leishmaniasis.
Hederagenin polyethylene glycol derivative and preparation method thereof
-
Paragraph 0027; 0041-0042, (2021/07/16)
The invention relates to the field of organic synthesis and medicinal chemistry, in particular to a hederagenin polyethylene glycol derivative with a novel structure and a preparation method of the hederagenin polyethylene glycol derivative. The compound disclosed by the invention is novel in structural type, improved in water solubility and excellent in tumor drug resistance reversion activity. The invention further provides a pharmaceutical composition for treating oral epithelial cancer, gastric cancer, lung cancer, cervical cancer, breast cancer or colon cancer and the like by being combined with clinically common anti-tumor drugs.
Synthesis of Anemoclemosides A and B, Two Saponins Isolated from Anemoclema glaucifolium
Bouillon, Marc E.,Bertocco, Katia,Bischoff, Laura,Buri, Michelle,Davies, Lucy R.,Wilkinson, Elizabeth J.,Lahmann, Martina
supporting information, p. 7470 - 7473 (2020/12/01)
Steroidal and triterpenoid saponins are attractive for their wide-ranging pharmacological properties. The triterpenoid saponins Anemoclemoside A and B are root constituents of the Chinese folk medicinal plant Anemoclema glaucifolium (Ranunculaceae). Both
